Lastly, Branco and colleagues performed a retrospective study of 108 HER2‐positive breast cancer patients and reported a HER2 discordance rate of 13.3% in patients treated with neoadjuvant therapy with residual disease; however, only three patients (including those with a pCR) received neoadjuvant dual HER2‐targeted treatment.8 This evidence concerns the gene ERBB2 and breast carcinoma.